Patricio S. Espinosa: Anticoagulation Is Not an Absolute Contraindication to Amyloid Therapy
Patricio S. Espinosa, Chief of Neurology and Institute Director at Espinosa Neuroscience Institute, shared a post on X:
”MYTH vs FACT: Amyloid Therapies & Anticoagulants
There is a common misconception that patients on anticoagulants (blood thinners) cannot receive amyloid-targeted therapies such as Kisunla (donanemab) and Leqembi (lecanemab).
MYTH:
Patients on anticoagulation are not candidates for amyloid therapies.
FACT:
With careful patient selection, strict adherence to protocols, and close monitoring, patients on anticoagulants can safely receive these therapies.
At Espinosa Neuroscience Institute, we have treated patients on anticoagulation with amyloid-targeted therapies without complications, by following:
- Rigorous MRI screening protocols
- Close monitoring for ARIA (Amyloid-Related Imaging Abnormalities)
- Individualized risk–benefit assessment
- Coordination of care across specialties
The key is not exclusion – it’s precision medicine.
These therapies are transforming how we treat mild cognitive impairment and early Alzheimer’s disease, and we should not deny patients access based on outdated assumptions.
Bottom line:
Anticoagulation is not an absolute contraindication – it requires expert management and protocol-driven care.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines